Citrafleet

Citrafleet is an oral solution that combines sodium picosulfate, magnesium oxide, and citric acid to provide bowel cleansing. It is marketed in the European Union as a prescription‑only laxative, classified under ATC code A06AX04. The formulation works as a stimulant and osmotic laxative, promoting colonic peristalsis and increasing intestinal water content to facilitate bowel evacuation. Citrafleet is supplied in a ready‑to‑drink liquid form for use patients.

Citrafleet is indicated for bowel preparation before diagnostic procedures and for the short‑term relief of constipation when other measures are insufficient.

- Colon cleansing prior to colonoscopy to ensure clear visualization of the colonic mucosa. - Preparation for flexible sigmoidoscopy or other endoscopic examinations of the lower gastrointestinal tract. - Adjunctive bowel evacuation in patients undergoing radiologic imaging that requires an empty colon. - Short‑term treatment of functional constipation unresponsive to dietary fiber or mild laxatives. - Use in pre‑operative protocols where a clean bowel is necessary for surgical access.

The safety profile of Citrafleet includes a range of gastrointestinal and systemic effects that vary in frequency.

Common: - Abdominal cramping or mild pain during the evacuation phase. - Diarrhea or loose stools occurring within several hours after ingestion. - Nausea or transient feeling of queasiness. - Electrolyte shifts such as mild hypokalemia, especially with inadequate fluid intake.

Serious: - Severe dehydration due to excessive fluid loss. - Marked electrolyte disturbances, including significant hypermagnesemia or hyponatremia. - Acute colonic perforation, though rare, reported in high‑risk patients.

When prescribing Citrafleet, clinicians should consider several precautionary measures to minimize risks and ensure effective bowel preparation.

- Assess renal function; impaired kidneys may reduce magnesium clearance and increase toxicity risk. - Evaluate electrolyte status before use, especially in patients with known imbalances. - Avoid in individuals with known bowel obstruction, perforation, or severe inflammatory bowel disease. - Ensure adequate oral fluid intake to prevent dehydration during the cleansing process. - Use with caution in elderly or frail patients who are more susceptible to fluid shifts. - Pregnancy and lactation status should be reviewed, as safety data are limited. - Discontinue other stimulant laxatives while using Citrafleet to avoid cumulative effects.

Citrafleet may interact with other medications or substances that affect fluid balance, electrolyte levels, or gastrointestinal motility.

Avoid: - Concurrent use of other osmotic or stimulant laxatives, which can amplify dehydration and electrolyte loss. - High‑dose antacids containing magnesium, increasing risk of hypermagnesemia. - Potassium‑sparing diuretics or ACE inhibitors, which may exacerbate potassium disturbances.

Use with caution: - Loop or thiazide diuretics, as they can further alter sodium and potassium balance. - Cardiac glycosides (e.g., digoxin) where electrolyte shifts may affect drug toxicity. - Anticoagulants, because rapid bowel movements may affect absorption of oral agents. - Oral antibiotics, as altered gut transit could modify their efficacy.